Latest Publications In The miRNA Field:

by Christoph on September 2, 2009

in Publications

mrSNP workflowmrSNP is a highly adaptable and performing web based tool for predicting the effect a 3′UTR SNP will have on miRNA binding. This tool has advantages over existing algorithms because it can assess the effect of novel SNPs on miRNA binding without requiring significant hands on time.

Project home page:
License: Free for commercial and academic use


MicroRNAs (miRNAs) bind to sites in the 3′untranslated regions (3′UTR) of a targeted messenger RNA (mRNA). Binding leads to degradation of the transcript or blocked translation resulting in decreased expression of the targeted gene. Single nucleotide polymorphisms (SNPs) have been found in 3′UTRs that disrupt normal miRNA binding or introduce new binding sites and some of these have been associated with disease pathogenesis. This raises the importance of detecting miRNA targets and [click to continue…]


Next-gen Sequencing and ncRNA, small RNA, miRNA data analysis workshopThe organizers are happy to announce the upcoming “NGS and non-coding RNA data analysis” workshop II (2014) 15-16 May, Plovdiv, Bulgaria

The SeqAhead COST action BM1006 is organizing a 2 day workshop with presentations on non-coding RNA (ncRNA) research, bioinformatics, data analysis and stimulating discussions between biologists and bioinformaticians. The registration for this COST WS is now open.

The Workshop will concentrate on current topics in NGS and non-coding RNAs, with special emphasis on data analysis. The ultimate goal of the workshop is to bring software developers, bioinformaticians and experimental scientists together, bridging the gap between users’ needs and developers’ goals.

Workshop Target:

-biologists with research in ncRNA (ncRNA, small RNAs, miRNAs) applying or planning to apply Next Generation Sequencing technologies
-bioinformaticians involved in data analysis or developing algorithms for data analysis of ncRNA data.

The workshop is open for everybody in the ncRNA and NGS field. The workshop is free of charge and participants have to pay their own hotel and travel. COST will offer travel reimbursement to some selected researchers and you will need to provide a poster abstract.
For more detailed information visit the WS homepage:

For more specific information please contact Dr. Vesselin Baev {}

{ 1 comment }

Researchers at the University of Oxford and the Scripps Research Institute recently published an article evaluating the use of several different RT-qPCR normalization strategies when profiling miRNA gene expression in mouse serum. In their research article entitled “Assessment of RT-qPCR Normalization Strategies for Accurate Quantification of Extracellular microRNAs in Murine Serum,” Roberts et. al. compare three miRNA expression normalization strategies: 1.) normalization of miRNA expression to the average Cq (Ct) of all measured miRNA genes, 2.) Normalization of gene expression to individual miRNAs such as miR-16, miR-223, or miR-31 (all miRNA genes previously identified as normalization controls in the literature), and 3.) Normalization to a ‘spike-in’ external control miRNA gene expressed in C. elegans (cel-miR-39).

Normalization strategies have been an increasingly important topic in miRNA expression studies. This is especially true when profiling miRNA expression in serum or tissues and when quantifying miRNA genes which can have considerable variability in their endogenous expression. The authors identified a panel of 124 serum miRNA genes present in all their samples between normal, dystrophic, and dystrophic-treated mice. Their results suggest that [click to continue…]


F6_mediumThe goal of pharmacogenetics is to better understand human response to both environmental toxins and drug treatment. Recently, several laboratories have investigated the hypothesis that microRNA regulation of drug metabolizing enzymes may influence their expression and ultimately effect enzymatic activity and patient drug toxicities. Researchers at the Pennsylvania State Hershey College of Medicine and Washington State University, Spokane, identified miR-491-3p as a microRNA regulator of UDP-Glucuronosyltransferase (UGT) gene family members. In their article ‘Regulation of the UDP-Glucuronosyltransferase 1A1 Expression and Activity by MicroRNA 491-3p’, miR-491-3p is identified to target and bind with the common 3’ UTR of several UGT1A sub family gene members. Endogenous miR-491-3p expression in vitro had a significant impact on the gene expression of UGT1A1, UGT1A3, and UGT1A6 genes. miR-491-3p expression also effected UGT1A1 protein expression and metabolic activity against the substrate raloxifene, a chemotherapeutic drug used in the prevention and treatment of breast cancer.

Interestingly, Dluzen et. al. also observed inter-individual variable expression of miR-491-3p in human liver. Nearly one-third of the 39 liver samples analyzed lacked [click to continue…]


starBase update: deciphering Pan-Cancer patterns of miRNAs, lncRNAs, ceRNAs and RNA-binding proteins from TCGA 14 cancer types

February 8, 2014

StarBase has been updated to explore Pan-Cancer pattern of lncRNAs, miRNAs, RNA-binding proteins (RBP) and their regulatory networks (ceRNA, coexpression) by mining expression profiles of miRNAs, lncRNAs and mRNAs across 14 cancer types (>6000 samples) from The Cancer Genome Atlas (TCGA) Data Portal (all data available without limitations). StarBase provides the following Pan-Cancer Analysis Services: […]

Read the full article →

DiamiR Reports Validation of Two Families of Brain-Enriched microRNAs as Highly Promising Blood-Based Biomarkers of Mild Cognitive Impairment

January 2, 2014

MONMOUTH JUNCTION, NJ–(Marketwired – January 02, 2014) - DiamiR, LLC, a molecular diagnostics company focused on the development and commercialization of innovative blood-based tests for detection and monitoring of neurodegenerative diseases and cancer, announced today the publication entitled “Plasma microRNA biomarkers for detection of mild cognitive impairment: biomarker validation study” in Aging. Mild Cognitive Impairment is a […]

Read the full article →

Marina Biotech and Mirna Therapeutics Amend License Agreement for the Development of microRNA-Based Therapeutics

January 2, 2014

Mirna Broadens Rights to Its Lead Cancer Therapeutic Candidate MRX34 BOSTON, MA and AUSTIN, TX–(Marketwired – Jan 2, 2014) – Marina Biotech, Inc. (PINKSHEETS: MRNA), a leading oligonucleotide-based drug discovery and development company, and Mirna Therapeutics, Inc. (Mirna), a privately-held biotechnology company pioneering microRNA (miRNA) replacement therapy for cancer, announced today that they have amended their […]

Read the full article →

Rosetta Genomics Granted U.S. Patent Allowance for the Use of microRNAs to Treat Liver Cancer

November 7, 2013

Expands the Company’s Patent Portfolio in Oncology Therapeutics PRINCETON, NJ and REHOVOT, ISRAEL–(Marketwired – Nov 7, 2013) – Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostics, announces receipt of a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) related to U.S. Patent Application No. 13/481,105 titled “Targeting […]

Read the full article →

microRNA-122: Positive Preclinical Profile of a GalNAc-conjugated anti-miR Supports Clinical Development for the Treatment of HCV

November 4, 2013

Regulatory Application for RG-101 to be Filed in the Near Term: Clinical Studies in Man Expected to Commence in Early 2014 LA JOLLA, Calif., Nov. 4, 2013 /PRNewswire/ — Regulus Therapeutics Inc. (NASDAQ: RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced that data demonstrating the positive preclinical profile of […]

Read the full article →

IntegraGen Obtains Exclusive License for Oncology Biomarker hsa-miR-31-3p

October 14, 2013

EVRY, France–(BUSINESS WIRE)– IntegraGen, a leading player in the development and marketing of molecular diagnostic testing in oncology and autism, announced today that it has finalized an agreement providing the company with exclusive licensing rights for the oncology biomarker hsa-miR-31-3p, a microRNA whose expression has been shown to be a predictor of progression free survival […]

Read the full article →